AACR 2024 ADC研发集锦—双抗ADC成重要开发趋势

▎ 追溯

一年一度的AACR会议即将开始，ADC依旧是本年度的热门话题，双抗ADC成为重要开发趋势。

3121 / 2 - Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers

T. O'Hare , J. Cleveland, V. M. Jansen, D. Dornan;
Elevation Oncology, Inc., Boston, MA

3122 / 3 - Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

N. Tsang ¹ , N. Veillard ¹ , E. Horsley ¹ , K. Havenith ¹ , N. Janghra ¹ , K. Zaitseva ¹ , C. Oblette ¹ , I. Kirby ¹ , P. W. Hogg ¹ , F. Zammarchi ² , L. de Haan ¹ , P. H. van Berkel ¹ ;
¹ ADC Therapeutics, London, United Kingdom, ² Myricx Bio, London, United Kingdom

3123 / 4 - Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

B. Min ¹ , S. Lee ¹ , W. Jung ¹ , L. Wang ² , Y. Sun ² , H. Kim ¹ , N.-G. Her ¹ , P. H. Song ² , G. Qin ² , D.-H. Nam ¹ ;
¹ Aimed Bio Inc., Seoul, Korea, Republic of, ² GeneQuantum Healthcare Suzhou Co., Ltd., Suzhou, China

3124 / 5 - MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies

Y. Wang ¹ , H. Li ¹ , H. Shen ² , W. Liu ¹ , S. Liu ¹ , K. Yin ¹ , H. Xu ¹ , X. Cui ¹ , W. Li ¹ , W. Liu ¹ , X. Wu ¹ , L. Yang ² , T. Ma ¹ , Z. Zhao ¹ , J. Wang ³ , F. Cui ² , L. Fang ² , M. Qin ³ , C. Hu ¹ ;
¹ Shanghai Miracogen Inc., Shanghai, China, ² Concept to Medicine Biotech Co., Ltd., Shanghai, China, ³ Lepu Biopharma Co., Ltd., Shanghai, China

3125 / 6 - TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors

F. G. Gomes, F. Muraca, G. M. Schmidt Garcia Moreira, K. Rösch, M. Bräutigam, P. Sondermann, M. Ocker ;
TACALYX GmbH, Berlin, Germany

3126 / 7 - A novel pegylated bispecific antibody-drug conjugate (P-BsADC) JY207b targeting cancers co-expressing PD-L1 and CD47

Y. Wen , Shumin Liu, Weidong Lyu, Yang Lei, Shuangyu Tan, Zibin Wu, Shuqiang Yin, Qiudong Zhuo, Dechun Wu;
Shenzhen Enduring Biotech, Ltd., Shenzhen, China

3127 / 8 - Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates

J. Wong , A. Hernández Rojas, A. Bissessur, L. T. Degefie, A. P. Sagoe-Wagner, S. Das, V. Fung, K. Yin, R. Duan, S. Lawn, L. Madera, C. Kim, A. Wu, M. E. Petersen, R. Colombo, J. R. Rich, S. D. Barnscher;
Zymeworks Inc., Vancouver, BC, Canada

3128 / 9 - HRA00184-C004, preclinical characterization of a novel tissue factor-targeted antibody-drug conjugate

H. Ying , L. You, N. He, S. Xu, P. Pu, S. Lin, J. Feng, Z. Zhang, X. Ye, M. Hu, F. He;
Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China

3129 / 10 - BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines

M. M. van der Lee ¹ , T. van Achterberg ¹ , K. Hersmus ¹ , A. Brouwers-Vos ² , M. van der Vleuten ¹ , M. Pruis ² , W. Kappers ¹ , G. Verheijden ¹ , G. Huls ² , G. van Wigcheren ¹ , R. Ubink ¹ , A. Sesink ¹ , A. MacInnes ¹ , J. Schuringa ² , W. Dokter ¹ ;
¹ Byondis B.V., Nijmegen, Netherlands, ² University Medical Center Groningen, University of Groningen, Groningen, Netherlands

3130 / 11 - In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992

T.-M. Kuo , T.-Y. Chang, J.-Y. Huang, W.-C. Tang, C.-J. Lin, Y.-C. Wu, C.-H. Lu, H.-C. Weng, Y.-J. Chen, Y.-H. Tsao, C.-Y. Wei, L. Shen, W.-F. Li, M.-T. Lai;
OBI Pharma, Inc, Taipei, Taiwan

3131 / 12 - Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers

P. Wong ¹ , L. He ² , K. Chow ¹ , K. Wong ¹ , C. O ¹ , D. Wong ³ , J. M. Luk ³ , P.-C. Lo ² , K. Wong ¹ ;
¹ Arbele Limited, Hong Kong, Hong Kong, ² City University of Hong Kong, Hong Kong, Hong Kong, ³ Arbele Corp, Seattle, WA

3132 / 13 - A novel dual drug antibody-drug conjugate targeting hTrop2 has synergetic anti-tumor activity in solid tumor models

J. Zhu , X. Zhao, E. Li, H. Xu, L. Nie, G. Chen, H. Wang;
BioRay Pharmaceutical Co., Ltd., San Diego, CA

3133 / 14 - A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics

H. Zhong, Y. Xiong, H. Huang, Y. Pan, N. Wang, B. Sun, S. Liu, W. Yuan, D. Liu, J. Fang, H. Bao ;
BiOneCure Therapeutics, Inc., Germantown, MD

3134 / 15 - SDP03923-000-9106, a novel and optimized LIV-1 ADC with superior anti-tumor efficacy in breast cancer xenograft models

Y. Gong , X. Sun, C. Yang, S. Chen, W. Zhang, C. Liao;
Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

3135 / 16 - BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

X. Hao ¹ , H. Li ¹ , X. F. Liu ² , J. Liu ¹ , W. Dai ¹ , Y. Pan ¹ , H.-H. Hu ¹ , J. Li ¹ , S. Xia ¹ , Q. Lyu ¹ , H. M. Davis ² , M. Chen ¹ , Z. Peng ¹ ;
¹ Biosion, Inc., Nanjing, China, ² Biosion USA, Inc., Newark, DE

3136 / 17 - Towards development of a novel biparatopic trop2-ADC

Y. Wu, B. Jiang, J. Rivera, F. Wang, J. Zhou, L. Liu, S. Hudson, W. Draper, J. Li, X. Min, H. Chen, Z. Wang ;
RemeGen Biosciences, Inc., South San Francisco, CA

3137 / 18 - Development of AT2604, a highly efficacious  ADC targeting alkaline phosphatases ALPP  and ALPPL2

B. K. S. Yeung , X. Koh, W. Ling, W. Tan, Y. Wu, X. Zhang, H. Tan, S. Liu, C. Zhong, B. Zou;
Axcynsis Therapeutics, Singapore, Singapore

3138 / 19 - Discovery of AT65474, a highly selective anti-CLDN6  ADC with a proprietary payload

C. Zhong , Y. Wu, X. Zhang, Y. Cheng, Q. Wang, P. Du, S. Liu, B. Zou;
Axcynsis Therapeutics, Singapore, Singapore

3139 / 20 - BL-M11D1, a novel CD33-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation

W. Wan ¹ , S. Zhao ¹ , S. Zhuo ¹ , Y. Zhang ¹ , L. Chen ¹ , R. Li ¹ , J. S. Khalili ² , X. Sa ¹ , Y. Yan ² , X. Shen ¹ , Y. Zhu ² ;
¹ Sichuan Baili Pharmaceutical Co., Ltd., Chengdu, China, ² SystImmune Inc., Redmond, WA

3140 / 21 - BL-M05D1, a novel claudin 18.2-targeting ADC, demonstrates specific potent anti-tumor efficacy in preclinical evaluation

W. Wan ¹ , K. Dinkel ² , A. Sanford ² , S. Zhao ¹ , S. Zhuo ¹ , Y. Zhang ¹ , L. Chen ¹ , R. Li ¹ , J. S. Khalili ² , X. Sa ¹ , Y. Yan ² , X. Shen ¹ , Y. Zhu ² ;
¹ Sichuan Baili Pharmaceutical Co., Ltd., Chengdu, China, ² SystImmune Inc., Redmond, WA

3141 / 22 - LCB02A an antibody drug conjugate (ADC) targeting CLDN18.2 expressing solid tumors

E. Baek , C.-W. Chung, C. Park, T. Jang, Y. Jeong, S.-A. Lee;
LegoChem Biosciences, Yuseong-gu, Korea, Republic of

3142 / 23 - NN3201, a novel c-Kit targeting ADC, exhibits robust preclinical anti-tumor efficacy in SCLC and GIST models

C. Kim, J. Cho, T. Wi, J. Moon, H.-J. Ko, J. Lee, J. Park, Y. Lee, S. Kim, J.-O. Kim, J. Song , S.-H. Lee, S. Park;
Novelty Nobility, lnc., Seongnam-si, Korea, Republic of

3143 / 24 - The ADC payload PNU-159682 is highly active in a wide range of cancer indications by inducing DNA damage and cell death via a distinct mode of action

M. Kaiser ¹ , U. Fiedler ¹ , D. Gerlach ² , N. Kraut ² , L. Bammert ¹ ;
¹ NBE Therapeutics, Basel, Switzerland, ² Boehringer Ingelheim, Vienna, Austria

3145 / 26 - HRA00242-C004, a novel anti-PSMA ADC with high DAR reveals potent in vitro and in vivo anti-tumor efficacy

G. Lin , H. Zhang, Z. Xu, L. You, Z. Xue, Y. Mao, X. Yang, B. Hu, S. Lin, J. Feng, Z. Zhang, X. Ye, M. Hu, F. He;
Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China

3146 / 27 - HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles

Q. Yao , C. Xue, Z. Xu, L. You, Z. Xue, Y. Mao, S. Lin, J. Feng, Z. Zhang, X. Ye, M. Hu, F. He;
Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China

3147 / 28 - DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

X. Jiang, J. Jia, H. Guo, X. Kong, Y. Xu, S. Ye, Y. Du, Z. Ye, Q. Cen, L. Zhang, Y. Chen, G. Chen, L. Bai, Y. Zheng, W. Zheng, J. Zheng, J. Wang, W. Li, Y. Huang, L. Zhao, Y. Xu, M. Liu, B. Chen, M. Dai, M. Chen, Z. Guo, Q. Yang, R. Y. Zhao ;
Hangzhou DAC Biotechnology Co., Ltd., Hangzhou City, China

3148 / 29 - ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers

E. J. Faivre ¹ , M. A. Pysz ² , E. Ó hAinmhire ¹ , L. Kreckler ¹ , K. Doyle ¹ , A. D'Souza ² , Z. Ding ² , T. Sondkar ² , D. Maji ² , F. Zhao ¹ , A. Phillips ¹ ;
¹ AbbVie Inc., North Chicago, IL, ² AbbVie Inc., South San Francisco, IL

3149 / 30 - Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies

T.-Y. Huang , Y.-C. Hsieh, K.-S. Fung, Y.-C. Huang, C.-S. Shia, M.-F. Chiang, N.-H. Wang, W.-F. Li, M.-T. Lai;
OBI Pharma, Inc., Taipei, Taiwan

1890 / 1 - HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models

Y. Xu , J. Liang, S. Jiang, H. Yang, H. Zhang, F. Mao, J. Zhu, J. He, N. Yang, J. Wang, W. Zhang, Y. Ren, W. Su;
HUTCHMED, Shanghai, China

1891 / 2 - Preclinical characterization of ADRX-0706: A next-generation anti-Nectin-4 antibody-drug conjugate with improved therapeutic window

A. M. Hau ¹ , M. Shahmoradgoli ¹ , D. Lee ¹ , W. Sisson ¹ , A. Wang ¹ , P. P. Challita ¹ , E. Nye ¹ , M. M. -. Kuo ¹ , A. Mahloch ¹ , M. Leung ¹ , O. Betancourt ¹ , A. Chu-Kung ¹ , M. Guo ² , H. Li ¹ , S. Rottmann ¹ , P. M. Challita-Eid ¹ ;
¹ Adcentrx Therapeutics, Inc., San Diego, CA, ² Adcentrx Therapeutics, Inc., Shanghai, China

1892 / 3 - KK2260: A fully human tetravalent bispecific antibody targeting TfR1 and EGFR for the treatment of EGFR-expressing tumors

K. Mitamura ¹ , H. Otsuki ² , K. Nakahashi ² , A. Kitagawa ² , M. Kamigaki ¹ , Y. Kurio ¹ , M. Inoue ¹ , Y. Uemura ¹ ;
¹ Kyowa Kirin Co., Ltd., Machida-Shi, Tokyo, Japan, ² Kyowa Kirin Co., Ltd., Sunto-gun, Shizuoka, Japan

1893 / 4 - OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

W.-F. Li , M.-F. Chiang, H.-C. Weng, J.-J. Yang, H.-S. Wu, C.-J. Lin, P.-T. Chiu, M.-T. Lai;
OBI Pharma, Inc., Taipei, Taiwan

1894 / 5 - Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors

L. Xiao ¹ , W. Lian ¹ , Q. Liu ¹ , Q. Zong ¹ , S. Song ¹ , S. Stann ² , J. Cai ¹ , T. Xue ¹ ;
¹ MediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China, ² MediLink Therapeutics USA, INC., Boston, MA

1896 / 7 - Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)

M. S. J. McDermott , N. A. O'Brien, M. Lu, J. Zhang, K. Gong, B. Hoffstrom, T. Luo, M. Liang, W. Jia, K. Chau, L. Presta, J. Glaspy, D. J. Slamon;
UCLA David Geffen School of Medicine, Los Angeles, CA

1897 / 8 - Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers

J. A. Scribner ¹ , J. G. Brown ² , T. Son ² , L. Jin ² , C. McKenzie ² , V. Nam ² , C. Bush ² , D. Quinonez ² , D. Ford ² , V. Gonzalez ² , J. Tamura ² , S. Gorlatov ² , H. Li ² , S. Butler ² , E. Bonvini ² , D. Loo ¹ ;
¹ MacroGenics, Inc., San Mateo, CA, ² MacroGenics, Inc., Rockville, MD

1898 / 9 - LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers

D. P. Fitzgerald ¹ , D. N. Doan ¹ , R. B. Peacock ¹ , S. M. Kahan ¹ , S. Lomash ¹ , S. Slocum ² , K. Jung ³ , H. Oh ³ , I. Meza ¹ , Y. Manzanarez ¹ , S. Selvam ¹ , D. B. Flies ¹ , C.-W. Chung ³ , S. Langermann ¹ ;
¹ NextCure, Inc., Beltsville, MD, ² AntibodyChem Biosciences, Boston, MA, ³ LegoChem Biosciences, Daejeon, Korea

1899 / 10 - Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models

M. Desbois ¹ , S. E. Calhoun ¹ , K. C. Hart ¹ , C. R. Denson ¹ , P. Yakkundi ¹ , T. J. Matthew ¹ , M. K. Leabman ¹ , S. Bilic ² , G. Hernandez ¹ , E. W. Humke ¹ , A. F. Candia ¹ , B. Keyt ¹ , A. M. Sinclair ¹ , M. F. Kotturi ¹ , B. T. Wang ¹ ;
¹ IGM Biosciences, Inc., Mountain View, CA, ² Vanadro, West Des Moines, IA

1900 / 11 - TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer

N. A. O'Brien , M. S. McDermott, J. Zhang, M. Lu, K. Gong, B. Hoffstrom, W. Jia, T. Luo, A. M. Madrid, M. Liang, J. A. Glaspy, D. J. Slamon;
UCLA - University of California Los Angeles, Los Angeles, CA

1901 / 12 - Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy in preclinical urothelial cancer models

R. Hein , K. Willis, G. LoMastro, S. Vasaikar, V. Gupta, K. Snead, S. Sandall, A. Kulukian;
Seagen, Bothell, WA

1902 / 13 - ADRX-0706 Nectin-4 antibody-drug conjugate PK/PD characterization elucidates its widened therapeutic window

M. Shahmoradgoli , A. Hau, D. Lee, A. Wang, P. P. Challita, O. Betancourt, W. Sisson, M. M. -. Kuo, K. Zhang, A. Goldson, S. Janssen, P. Datta, F. Acosta, A. Chu-Kung, H. Li, P. M. Challita-Eid, S. Rottmann;
Adcentrx Therapeutics, Inc., San Diego, CA

1904 / 15 - Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer

J. A. Scribner ¹ , J. G. Brown ² , T. Son ² , L. Jin ² , C. McKenzie ² , V. Nam ² , C. Bush ² , D. Quinonez ² , J. Tamura ² , S. Gorlatov ² , H. Li ² , S. Butler ² , E. Bonvini ² , D. Loo ¹ ;
¹ MacroGenics, Inc., San Mateo, CA, ² MacroGenics, Inc., Rockville, MD

1905 / 16 - The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia

R. B. Lock ¹ , K. Evans ¹ , B. Watts ¹ , E. P. Bowman ² , S. Neuhauser ³ , T. Stearns ³ , J. H. Chuang ³ , V. M. Phillip ³ , K. A. Jessen ⁴ , E. L. Jocoy ⁵ , C. J. Bult ³ , B. A. Teicher ⁶ , M. A. Smith ⁶ ;
¹ UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, Australia, ² Merck & Co., Rahway, NJ, ³ The Jackson Laboratory, Bar Harbor, ME, ⁴ Formerly VelosBio, Inc., San Diego, CA, ⁵ The Jackson Laboratory, Sacramento, CA, ⁶ National Cancer Institute, Bethesda, MD

1907 / 18 - MYTX-011: A pH-dependent anti-cMET ADC with increased payload delivery in vivo and potent activity against cMET-expressing tumors of various epithelial origins

D. Kanojia , W. Comb, W. Israelsen, F. Colombo, L. Nie, N. Gera, T. Chittenden, B. Fiske;
Mythic Therapeutics, Waltham, MA

1909 / 20 - Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology

D. Lee ¹ , S. Rottmann ¹ , A. Wang ¹ , P. P. Challita ¹ , A. M. Hau ¹ , W. Sisson ¹ , M. M. -. Kuo ¹ , K. Zhang ¹ , M. Leung ¹ , A. Mahloch ¹ , E. Nye ¹ , P. Datta ¹ , S. Janssen ¹ , F. Acosta ¹ , O. Betancourt ¹ , M. Shahmoradgoli ¹ , A. Chu-Kung ¹ , M. Guo ² , P. M. Challita-Eid ¹ , H. Li ¹ ;
¹ Adcentrx Therapeutics, Inc., San Diego, CA, ² Adcentrx Therapeutics, Inc., Shanghai, China

1911 / 22 - Dato-DXd mediates anti-tumor activity in preclinical TROP2-expressing intracranial tumor model

K. Jones, M. Suksomboon, S. rosenthal, J. Gordon, C. Reimer, M. Sung, C. Rane ;
AstraZeneca, Waltham, MA

1912 / 23 - Targeting Trop-2 with sacituzumab govitecan (IMMU-132) suppresses the tumor growth in diffuse large B cell lymphoma

J. Ting , M.-F. Wei, H.-W. Lee, K.-H. Lan, A.-L. Cheng, S.-H. Kuo;
National Taiwan University College of Medicine, Taipei City, Taiwan

1858 / 2 - Discovery of AT86474, a highly efficacious anti-ROR1 ADC utilizing a proprietary payload

B. Tan , X. Zhang, Y. Wu, Y. Cheng, S. Liu, P. Du, C. Zhong, B. Zou;
Axcynsis Therapeutics, Singapore, Singapore

1862 / 6 - ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications

S. Lawn , A. Hernandez Rojas, R. Colombo, J. Wong, K. Wu, V. Fung, M. Lasalle, M. E. Petersen, L. Degefie, A. Sagoe-Wagner, D. Urosev, L. Yang, A. Wu, C. Kim, A. Chua, K. Stahl, G. C. Winters, J. C. H. Fann, J. Rich, S. Barnscher;
Zymeworks Inc., Vancouver, BC, Canada

1865 / 9 - HDP-102 - a CD37-targeting Amanitin-based-ADC for the treatment of NHL - non-clinical data package

S.-J. Neuberth ¹ , K. Decker ² , C. Orlik ¹ , I. Dranova ¹ , A. Pálfi ¹ , T. Hechler ¹ , A. Pahl ² , M. Kulke ² ;
¹ Heidelberg Pharma Research GmbH, Ladenburg, Germany, ² Heidelberg Pharma AG, Ladenburg, Germany

1870 / 14 - LCB36, a bi-specific antibody drug conjugate (BsADC) utilizing ConjuAll conjugation technology and proprietary prodrug payload selectively activated in cancer cells for treating B-cell blood cancers expressing CD20 and/or CD22

W. Kim , N. Choi, C.-W. Chung, H. Oh;
LegoChem Biosciences, Inc, Daejeon, Korea

1872 / 16 - A next generation treatment for Nectin-4 positive cancers - Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload

D. Sagar ¹ , M. Srinivasan ² , K. Lindquist ² , Q. Guo ¹ , W. Wong ¹ , M. B. Lebron ¹ , R. Sattler ¹ , J. Zhou ² , W. Helms ³ , J. Boyles ⁴ , P. Verdino ⁵ , X. Zhao ² , Y. Mak ² , J. Park ² , R. Holmgaard ¹ , K. Driscoll ¹ , O. Duramad ² , K. Bedard ² ;
¹ Loxo@Lilly, New York, NY, ² Loxo@Lilly, South San Francisco, CA, ³ Loxo@Lilly, Silver Springs, MD, ⁴ Eli Lilly and Company, Indianapolis, IN, ⁵ Eli Lilly and Company, San Diego, CA

1882 / 26 - DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

J. Zhu, J. Jia, H. Guo, X. Kong, Y. Du, Z. Ye, L. Zhang, Y. Chen, L. Bai, Y. Zheng, W. Zheng, J. Zheng, J. Wang, W. Li, Y. Huang, Z. Fan, M. Liu, B. Chen, M. Dai, F. Du, M. Chen, Z. Guo, Q. Yang, R. Y. Zhao ;
Hangzhou DAC Biotechnology Co., Ltd., Hangzhou City, China

1883 / 27 - A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors

X. Cai, M. Cao, H. Guo, Q. Yang, Y. Chen, X. Kong, Y. Du, Z. Ye, Z. Guo, L. Zhang, L. Bai, J. Jia, Y. Zheng, W. Zheng, J. Zheng, W. Li, Y. Huang, Z. Fan, B. Chen, Y. Yang, M. Dai, R. Y. Zhao ;
Hangzhou DAC Biotechnology Co., Ltd., Hangzhou City, China

1884 / 28 - DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies

X. Kong, H. Guo, Y. Du, Z. Ye, Y. Chen, Z. Guo, L. Zhang, L. Bai, J. Jia, Y. Zheng, W. Zheng, J. Zheng, W. Li, Y. Huang, Z. Fan, M. Liu, B. Chen, M. Dai, J. Wang, F. Du, M. Chen, Q. Yang, R. Y. Zhao ;
Hangzhou DAC Biotechnology Co., Ltd., Hangzhou City, China

1885 / 29 - Developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatment

X. Zhao ¹ , J. Zhu ¹ , z. Wu ² , Y. Li ¹ , J. Li ¹ , Y. Zhou ² , L. Nie ² , H. Wang ² , G. Chen ¹ ;